QURE logo

uniQure NV (QURE) Company Overview

Profile

Full Name:

uniQure N.V.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

February 5, 2014

Indexes:

Not included

Description:

uniQure NV is a biotechnology company focused on developing gene therapies for genetic diseases. They aim to provide innovative treatments that can potentially cure conditions by correcting genetic defects. Their work includes research, development, and commercialization of these advanced therapies to improve patient outcomes.

Key Details

Price

$14.63

Annual Revenue

$15.84 M(-85.12% YoY)

Annual EPS

-$6.47(-138.75% YoY)

Annual ROE

-90.24%

Beta

1.88

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 5, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 27, 25 HC Wainwright & Co.
Buy
Jan 21, 25 RBC Capital
Outperform
Dec 19, 24 Mizuho
Neutral
Dec 16, 24 Stifel
Buy
Dec 12, 24 Goldman Sachs
Neutral
Dec 11, 24 RBC Capital
Outperform
Dec 11, 24 Leerink Partners
Outperform
Dec 11, 24 Guggenheim
Buy
Dec 10, 24 Raymond James
Strong Buy
Dec 10, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

uniQure Announces Proposed Public Offering
uniQure Announces Proposed Public Offering
uniQure Announces Proposed Public Offering
QURE
globenewswire.comJanuary 7, 2025

LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
QURE
fool.comDecember 15, 2024

Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
QURE
zacks.comDecember 11, 2024

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
QURE
zacks.comNovember 29, 2024

The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes uniQure (QURE) a New Buy Stock
What Makes uniQure (QURE) a New Buy Stock
What Makes uniQure (QURE) a New Buy Stock
QURE
zacks.comNovember 28, 2024

uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
QURE
zacks.comNovember 5, 2024

UniQure (QURE) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $1.88 per share a year ago.

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
QURE
zacks.comAugust 1, 2024

UniQure (QURE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.44 per share a year ago.

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
QURE
globenewswire.comJuly 23, 2024

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~

What Led To A 150% Rise In UniQure Stock In A Week?
What Led To A 150% Rise In UniQure Stock In A Week?
What Led To A 150% Rise In UniQure Stock In A Week?
QURE
forbes.comJuly 12, 2024

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
QURE
zacks.comJuly 10, 2024

The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for uniQure NV?
  • Does uniQure NV pay dividends?
  • What sector is uniQure NV in?
  • What industry is uniQure NV in?
  • What country is uniQure NV based in?
  • When did uniQure NV go public?
  • Is uniQure NV in the S&P 500?
  • Is uniQure NV in the NASDAQ 100?
  • Is uniQure NV in the Dow Jones?
  • When was uniQure NV's last earnings report?
  • When does uniQure NV report earnings?
  • Should I buy uniQure NV stock now?

What is the ticker symbol for uniQure NV?

The ticker symbol for uniQure NV is NASDAQ:QURE

Does uniQure NV pay dividends?

No, uniQure NV does not pay dividends

What sector is uniQure NV in?

uniQure NV is in the Healthcare sector

What industry is uniQure NV in?

uniQure NV is in the Biotechnology industry

What country is uniQure NV based in?

uniQure NV is headquartered in Netherlands

When did uniQure NV go public?

uniQure NV's initial public offering (IPO) was on February 5, 2014

Is uniQure NV in the S&P 500?

No, uniQure NV is not included in the S&P 500 index

Is uniQure NV in the NASDAQ 100?

No, uniQure NV is not included in the NASDAQ 100 index

Is uniQure NV in the Dow Jones?

No, uniQure NV is not included in the Dow Jones index

When was uniQure NV's last earnings report?

uniQure NV's most recent earnings report was on Nov 5, 2024

When does uniQure NV report earnings?

The next expected earnings date for uniQure NV is Feb 28, 2025

Should I buy uniQure NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions